SARS vaccine at least 2 years away, WHO says

SARS

Nov 5, 2003 (CIDRAP News) – It will probably take between 2 and 5 years to develop a SARS (severe acute respiratory syndrome) vaccine, depending on the scale of future SARS outbreaks, the World Health Organization (WHO) predicted today.

In a statement released after a meeting of leading SARS researchers from 15 countries, the WHO said, "The first clinical trial on an inactivated SARS vaccine could begin as early as January 2004. However, it is difficult to say when a vaccine might be available. A resurgence of SARS may accelerate the process and result in a vaccine within two years. If there is no big outbreak of SARS then the vaccine will follow the classical development path, and would not be ready for four to five years."

WHO Director-General Dr. LEE Jong-Wook called vaccine development efforts encouraging but said any SARS resurgence in the near term will have to be managed with surveillance, early diagnosis, contact tracing, hospital infection control, and international reporting.

Experts at the 2-day meeting in Geneva reviewed progress in SARS vaccine development and identified ways to speed development and testing, the statement said. Their discussion was guided by extensive available information on vaccines against animal diseases caused by coronaviruses other than the SARS virus.

Dr. Marie-Paule Kieny, director of the WHO Initiative for Vaccine Research, said, "If we are to develop a SARS vaccine more quickly than usual, we have to continue to work together on many fronts at once, on scientific research, intellectual property and patents issues and accessibility. It is a very complicated process involving an unprecedented level of international cooperation which is changing the way we work."

The researchers considered how intellectual property issues can help rather than hinder the rapid development of SARS vaccines and ensure that any vaccine will be available in both industrialized and developing countries, the WHO said.

The group also discussed regulatory issues, including the prospect that SARS vaccines may have to be licensed without data from human efficacy trials. Given the severity of the disease and the urgent need for a vaccine, human efficacy trials might be inappropriate, the WHO said.

See also:

WHO news release
http://www.who.int/mediacentre/releases/2003/pr83/en/

This week's top reads

  1. FDA significantly limits COVID-19 vaccine recommendations

    Critics said today’s announcement is more evidence of the current administration’s willingness to undermine public trust in vaccines.

    Stephanie Soucheray
    FDA building

  2. USDA suspends southern border livestock imports over New World screwworm threat

    As cattle detections track northward, Mexico recently reported its first human case.

    Lisa Schnirring
    screwworm larva

  3. Meta-analysis: Zika-infected pregnant moms 4 times more likely to have babies with microcephaly

    Five of 22 studies noted that over 50% of newborns had microcephaly, and the same number of studies observed that over 5% had congenital Zika syndrome. 

    Mary Van Beusekom

  4. Woman dies of Creutzfeldt-Jakob almost 50 years after taking prion-contaminated growth hormone

    The patient, who presented with gait imbalance and tremors, wasn't diagnosed until she was in a coma, shortly before she died.

    Mary Van Beusekom
    Woman in hospital bed

  5. HHS expected to discontinue COVID vaccine recommendations for some groups

    When CDC advisers widened their recommendation in 2023, most members were swayed by data, including those for long COVID, showing that no group is at low risk for the virus.

    Lisa Schnirring

  6. Data suggest COVID-19 reinfections less likely to cause long COVID

    The risk of long COVID was two to three times higher after the initial infection (14.8%) than after first (5.8%) or second (5.3%) reinfections.

    Stephanie Soucheray
    LONG COID

  7. WHO advisers say current strains OK for COVID vaccine production

    Current vaccine strains show high neutralization against the latest variants, but the LP.8.1 antigen may provide similar or moderately higher cross-reactive antibody response.

    Lisa Schnirring
    senior vaccination

  8. Texas announces more measles cases, including first in Dallas area

    Two cases near the Dallas area are now included in the large outbreak, which now totals 717 cases.

    Lisa Schnirring

  9. US measles outbreak grows to 1,024 cases

    Texas remains the country's hot spot, with 718 cases. 

    Chris Dall
    Doctor treating child with measles

  10. Saudi Arabia confirms 9 MERS cases, including hospital cluster

    Since 2023, the country has ramped up MERS-CoV testing as part of sentinel surveillance.

    Lisa Schnirring
    hospital isolation

Our underwriters